Publication | Closed Access

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Gbrca MMedicineGynecologyPathologyCancer TreatmentOncologyEndocrine-related CancerGermline Brca -MutatedOvarian Cancer